Ironwood Pharma Inc Class A (IRWD) valuation
Ironwood Pharma P/E ratio history
Ironwood Pharma trades at 4.6 times its earnings over the last twelve months and 2.6 times the earnings analysts expect over the next twelve. At its last 5 fiscal year ends its P/E ranged from 3.6 (year to Dec 2021) to 102.4 (year to Dec 2019), with a median of 17.3.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $3.37 | $0.13 | 25.9 | 9.6 |
| Dec 31, 2024 | $4.43 | -$0.01 | n/m | — |
| Dec 31, 2023 | $11.44 | -$6.51 | n/m | — |
| Dec 31, 2022 | $12.39 | $0.97 | 12.8 | — |
| Dec 31, 2021 | $11.66 | $3.23 | 3.6 | 6.9 |
| Dec 31, 2020 | $11.39 | $0.66 | 17.3 | — |
| Dec 31, 2019 | $13.31 | $0.13 | 102.4 | — |
| Dec 31, 2018 | $10.36 | — | n/m | — |
| Dec 31, 2017 | $14.99 | — | n/m | — |
| Dec 31, 2016 | $15.29 | — | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Ironwood Pharma valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Ironwood PharmaIRWD | $576M | 4.6 | 2.6 | 1.5 |
| GeronGERN | $574M | — | — | 2.8 |
| Fulgent GeneticsFLGT | $586M | — | — | 1.8 |
| Mimedx GroupMDXG | $566M | — | 70.4 | 1.9 |
| Aclaris TherapeuticsACRS | $554M | — | — | 67.4 |
| Bicara TherapeuticsBCAX | $600M | — | — | — |
| Myriad GeneticsMYGN | $600M | — | — | 0.7 |
| Zevra TherapeuticsZVRA | $608M | 10.9 | 9.2 | 4.5 |
| Candel TherapeuticsCADL | $610M | — | — | — |
| Peer median | 10.9 | 39.8 | 2.3 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: IRWD financials · IRWD returns
No forecast, no recommendation. This page describes Ironwood Pharma Inc Class A from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.